• Johnson & Johnson (NYSE:JNJ) reported earnings per share of $2.46, beating estimates and showcasing a revenue of $24.56 billion.
• The company's growth is significantly driven by its cancer and autoimmune drug segments, indicating a 9% increase in revenue during the fourth quarter.
• JNJ's financial metrics reveal a solid market position with a P/E ratio of approximately 21.10 and a price-to-sales ratio of about 5.71.

Johnson & Johnson (NYSE:JNJ) is a leading healthcare company known for its wide range of products, including pharmaceuticals, medical devices, and consumer health goods. The company competes with other major players like Pfizer and Merck in the pharmaceutical industry. On January 21, 2026, JNJ reported earnings per share of $2.46, surpassing the estimated $2.43, and revenue of approximately $24.56 billion, exceeding the estimated $24.16 billion.

The company's strong performance is largely driven by its cancer and autoimmune drug segments, which contributed to a 9% increase in revenue during the fourth quarter. This growth is part of a new strategy that has positioned JNJ to potentially reach $100 billion in revenue next year. Despite a recent drug pricing deal with the Trump administration, which is expected to impact profits by "hundreds of millions of dollars," JNJ remains optimistic about its 2026 sales and profit projections.

JNJ's financial metrics provide insight into its market position. The company has a price-to-earnings (P/E) ratio of approximately 21.10, indicating the price investors are willing to pay for each dollar of earnings. Its price-to-sales ratio is about 5.71, reflecting the value placed on each dollar of sales. The enterprise value to sales ratio stands at around 6.00, suggesting the company's total valuation relative to its sales.

The enterprise value to operating cash flow ratio is approximately 22.86, showing how the company's valuation compares to its cash flow from operations. With an earnings yield of about 4.74%, JNJ offers a return on investment for shareholders. The company's debt-to-equity ratio of approximately 0.58 indicates a moderate level of debt relative to equity, while a current ratio of around 1.07 suggests its ability to cover short-term liabilities with short-term assets.